HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Biosimilars of filgrastim in autologous stem cell transplant: reduction in granulocyte-colony stimulating factor costs, but similar effects on bone marrow recovery.

Abstract
Granulocyte-colony stimulating factors (G-CSFs) enhance bone marrow (BM) recovery after autologous stem cell transplant (ASCT) in patients with lymphoma and myeloma. Few publications exist that discuss the use of filgrastim biosimilars after ASCT. We conducted a single-center retrospective study in patients with lymphoma and myeloma treated at Brest Hospital to assess the cost reductions related to and the efficiency and safety of filgrastim biosimilars. We identified 65 patients with lymphoma or myeloma treated with filgrastim biosimilars for ASCT and compared 19 parameters of these patients, including BM recovery, side effects, infectious complications and treatment costs, with published historical data on a cohort of 50 patients treated with classic filgrastim. We observed a significant reduction of G-CSF costs in both groups but did not observe a change in total hospitalization costs (representing less than 2% of the costs) between groups. Additionally, we did not observe differences between the two groups in BM recovery, infectious complications, side effects or the other studied parameters. In this retrospective study, the absence of differences between groups after ASCT in lymphoma and myeloma led us to believe that these drugs could be safely and effectively used for such indications without a significant impact on hospitalization costs. A prospective study should be conducted to confirm our results.
AuthorsJean-Christophe Ianotto, Françoise Ngo Sack, Marie-Anne Couturier, Adrian Tempescul, Nathalie Mugnier, Pascal Delepine, Gaelle Guillerm, Christian Berthou
JournalLeukemia & lymphoma (Leuk Lymphoma) Vol. 55 Issue 1 Pg. 74-7 (Jan 2014) ISSN: 1029-2403 [Electronic] United States
PMID23566160 (Publication Type: Journal Article)
Chemical References
  • Biosimilar Pharmaceuticals
  • Recombinant Proteins
  • Granulocyte Colony-Stimulating Factor
  • Filgrastim
Topics
  • Adult
  • Aged
  • Biosimilar Pharmaceuticals (economics, therapeutic use)
  • Drug Costs
  • Female
  • Filgrastim
  • Granulocyte Colony-Stimulating Factor (economics, therapeutic use)
  • Hematopoietic Stem Cell Transplantation (adverse effects)
  • Humans
  • Lymphoma (therapy)
  • Male
  • Middle Aged
  • Multiple Myeloma (therapy)
  • Recombinant Proteins (economics, therapeutic use)
  • Retrospective Studies
  • Transplantation, Autologous
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: